Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Countries: UK Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 15 results found since Jan 2013.
Incidence of Stroke in People With Diabetes Compared to Those Without
Diabetes: A Systematic Review
Conclusion The considerable differences between results can partly be
explained by differences in study designs, statistical methods, definitions of
stroke, and methods used to identify patients with diabetes. The lack of
evidence arising from these differences ought to be rectified by new
studies. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
Source: Experimental and Clinical Endocrinology and Diabetes - July 17, 2023 Category: Endocrinology Authors: Kvitkina, Tatjana Narres, Maria Claessen, Heiner Metzendorf, Maria-Inti Richter, Bernd Icks, Andrea Tags: Review Source Type: research
Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
ConclusionIn patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk.
Source: Diabetes Therapy - September 20, 2018 Category: Endocrinology Source Type: research
Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988 –2014
Publication date: Available online 27 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mohammed K Ali, Kai McKeever Bullard, Sharon Saydah, Giuseppina Imperatore, Edward W Gregg Background There is controversy over the usefulness of prediabetes as a diagnostic label. Using data from US National Health and Nutrition Examination Surveys (NHANES) between 1988 and 2014, we examined the cardiovascular and renal burdens in adults with prediabetes over time and compared patterns with other glycaemic status groups. Methods We analysed cross-sectional survey data from non-pregnant adults aged 20 years an...
Source: The Lancet Diabetes and Endocrinology - February 28, 2018 Category: Endocrinology Source Type: research
Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: Available online 11 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. Methods PATHWA...
Source: The Lancet Diabetes and Endocrinology - April 12, 2018 Category: Endocrinology Source Type: research
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Prospective Studies Collaboration and Asia Pacific Cohort Studies CollaborationLGnatiucWGHerringtonJHalseyJTuomilehtoXFangHCKimDDe BacquerAJDobsonMHCriquiDRJacobsJrDALeonSAEPetersHUeshimaPSherlikerRPetoRCollinsRRHuxleyJREmbersonMWoodwardSLewingtonNAokiHArimaEArnesenAAromaaGAssmannDLBachmanCBaigentHBartholomewABenetosCBengtssonDBennettCBjörkelundHBlackburnKBonaaEBoyleRBroadhurstJCarstensenLChamblessZChenSKChewRClarkeCCoxJDCurbRD'AgostinoCDateGDavey SmithGDe BackerSSDhaliwalXFDuanPDucimetiereSDuffyHEliassenPElwoodJEm...
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
Publication date: July 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 7Author(s): L Gnatiuc, WG Herrington, J Halsey, J Tuomilehto, X Fang, HC Kim, D De Bacquer, AJ Dobson, MH Criqui, DR Jacobs, DA Leon, SAE Peters, H Ueshima, P Sherliker, R Peto, R Collins, RR Huxley, JR Emberson, M Woodward, S LewingtonSummaryBackgroundSeveral studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether ...
Source: The Lancet Diabetes and Endocrinology - July 5, 2018 Category: Endocrinology Source Type: research
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: June 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 6Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown, The British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study GroupSummaryBackgroundIn the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did ...
Source: The Lancet Diabetes and Endocrinology - July 5, 2018 Category: Endocrinology Source Type: research
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
Publication date: July 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 7Author(s): L Gnatiuc, WG Herrington, J Halsey, J Tuomilehto, X Fang, HC Kim, D De Bacquer, AJ Dobson, MH Criqui, DR Jacobs, DA Leon, SAE Peters, H Ueshima, P Sherliker, R Peto, R Collins, RR Huxley, JR Emberson, M Woodward, S LewingtonSummaryBackgroundSeveral studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether ...
Source: The Lancet Diabetes and Endocrinology - July 10, 2018 Category: Endocrinology Source Type: research
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: June 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 6Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown, The British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study GroupSummaryBackgroundIn the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did ...
Source: The Lancet Diabetes and Endocrinology - July 10, 2018 Category: Endocrinology Source Type: research
